Based on our data, DLK1-directed ADCs would also be expected to have greater activity in ACC tumors with positive but low DLK1 expression due to decreased adrenocortical differentiation and ABCB1 expression (Fig. 4L). This evidence concerns the gene ABCB1 and adrenal cortex carcinoma.